New nanoparticles for the delivery of antibiotics to fight antimicrobial-resistance

Technology description

The antimicrobial resistance phenomenon has long been an important sanitary emergency, making it necessary to resort to "last choice" antibiotics such as colistin, little used due to toxicity and low levels that can be reached at the site of infection. To counteract this we developed a new delivery system of drug able to reduce toxicity, increase efficacy and overcome antimicrobial resistance. 
The proposed invention consist of nanoparticles that are a lipophilic multireservoir in which the incorporated colistin is molecularly dispersed. The formulation presents a matrix of albumin, a biocompatible molecule with low costs of production respect to other formulations containing phospholipids, and is chitosan- coated to increase mucoadesivity. The drug is not toxic and hemolytic, highly stable and allows a prolonged release over time. The production process is short, not complex and easily scalable, reducing the costs of production. Respect to other albumin nanoparticles currently in use, as antitumoral drug, the formulation is innovative as the colistin is not chemically bound to albumin. The results obtained with this new delivery system show an increased antimicrobial and antibiofilm activity towards colistin resistant and sensible bacteria.

  • Topical treatment of skin infections in burn patients
  • Topical treatment of chronic wounds and ulcers
  • Inhalation/nebulization treatment  of chronic respiratory infections in cystic fibrosis patients 
Key advantages
  • Low costs of production
  • Short production times
  • Possible use of the two forms of colisitin: colistin sulphate  and methanesulfonate
  • Prolonged release of the drug over time 
Filing date and application number

Filing date: 29/09/2020

Application number: 102020000022984




Università degli Studi di Torino